Novartis announced a restructuring plan yesterday which involves cutting between 400 - 440 development jobs in Switzerland over the next few years.
Another 240 jobs are at risk in the USA.
The Basel-based pharmaceutical company currently employs over 10’000 people, around 3’000 of whom are dedicated to development.
The company, which is consistently ranked as one of the global top 5 pharmaceutical companies in the world, insists that its research activities will remain unaffected.